Amgen Inc. (AMGN-Q)

Phase 2 drug in the GLP-1 space -- not as mature as LLY's drug, but you don't pay as much for this company either. Trades ~14x earnings, compared to 50x for LLY. And that's more his style of investing.

Diversity is good in the bio pharma space. It is a fully diversified large cap and he would have it as a core holding.

A dividend play for 2025 at 3.65%. Not sexy, but consistently generates earnings, free cash flow, and each year grows its dividend. Offers growth wealth generation over time.

He still believes in their key drug, Repatha. His concern lies with their weight-loss drug and their disappointing results.

Today's downgraded doesn't bother him. These calls go back and forth often. Their weight-loss drug could add $10 billion revenues. A good time to own this.

They just bought Horizon Therapeutics, a growth engine, and have a weight-loss drug in phase 2 trials that is promising facing a huge market. They trade at a decent PE and enjoy good growth from their core drugs.

He prefers Amgen, because their weight-loss drug is under trial and not priced into the stock yet. And it trades at a lower PE than these peers.

Trades at a healthy 15x earnings and 66% gross margin (56% in the sector). It pays a 3% dividend. They just bought Horizon Therapeutics which adds growth. Their early-stage obesity drug shows great promise in a $100 billion potential market.

Owns this instead of NVO. A much less troublesome valuation. Also has a weight-loss drug in trial. You want to be in before the good news, not after.

He's surprised with how strongly shares are soaring on phase 3 trial results of their obesity drug. They're a little late to the party in these drugs, but theirs you would take less often their than peers'. Also, a recent acquisition makes them double-digit revenue growers and is accretive. Loves the dividend growth too.

Legacy products that continue to do well. But new products are contributing well, too. Latest acquisition adding significantly to growth profile. Reasonable multiple of 12-13x, good prospects for growth. Out of favour, along with many healthcare stocks. Good, long-term hold.

Pays a 3.2% dividend and trades at a 14x forward PE.